Kenneth McGrath serves as Chief Financial Officer at OraSure Technologies, Inc., a global leader in point-of-care diagnostics and other innovative medical technologies. With more than 25 years of experience in the pharmaceutical and biotechnology sectors, McGrath has built a distinguished career marked by strategic financial leadership and operational excellence. His early roles included progressive finance positions at companies like Endo Pharmaceuticals, where he rose to Senior Director of Finance, overseeing global financial planning, treasury operations, and mergers and acquisitions. Prior to joining OraSure in 2021, McGrath was CFO at BioDelivery Sciences International (BDSI) from 2017 to 2021, guiding the company through significant revenue growth, debt restructuring, and its successful acquisition by Ameda Pharmaceuticals in a $263 million deal. Before BDSI, he held the position of Vice President of Finance and Treasurer at Puma Biotechnology, where he managed capital raises exceeding $1 billion and supported the commercial launch of the company's breakthrough oncology drug, Nerlynx. In his current role at OraSure, McGrath directs all financial functions, including strategic planning, investor relations, SEC reporting, and risk management. He has been instrumental in navigating the company's expansion during the COVID-19 pandemic through its InteliSwab rapid antigen test, while driving cost efficiencies and positioning OraSure for growth in oral fluid diagnostics for HIV, hepatitis, and substance abuse testing. His expertise continues to bolster OraSure's financial stability and long-term shareholder value.